TAK-079

DRUG5 trials

Sponsors

Takeda, Millennium Pharmaceuticals, Inc.

Conditions

Autoimmune DiseaseLupus Erythematosus, SystemicMultiple MyelomaMyasthenia GravisPrimary Immune ThrombocytopeniaSystemic Lupus Erythematosus

Phase 1

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants

CompletedNCT02219256

TakedaAutoimmune Disease

Start: 2014-08-31End: 2016-04-30Updated: 2017-05-03

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

CompletedNCT03724916

Millennium Pharmaceuticals, Inc.Lupus Erythematosus, Systemic, Systemic Lupus Erythematosus

Start: 2018-11-26End: 2021-11-04Updated: 2024-03-29

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

CompletedNCT03984097

TakedaMultiple Myeloma

Start: 2019-07-29End: 2026-03-25Updated: 2026-04-09

Phase 2

A Study of TAK-079 in People With Generalized Myasthenia Gravis

CompletedNCT04159805

TakedaMyasthenia Gravis

Start: 2020-01-14End: 2022-07-12Updated: 2023-06-02

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

CompletedNCT04278924

TakedaPrimary Immune Thrombocytopenia

Start: 2020-11-09End: 2024-04-29Updated: 2025-06-15

Related Papers

A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia

New England Journal of Medicine2026-04-08

Trial in progress: Study design of a randomized, phase 3 trial evaluating the efficacy and safety of mezagitamab (TAK-079) compared with placebo in adults with chronic primary immune thrombocytopenia

Blood2025-11-03

Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma

Blood Neoplasia2024-09-191 citations